Bemarituzumab Biosimilar – Anti-FGFR2 mAb – Research Grade from ProteoGenix; catalogue PX-TA1492; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Bemarituzumab is a humanized monoclonal antibody targeting the human fibroblast growth factor receptor 2b (FGFR2b). This humanized glycosylated biosimilar belong to the family of immunoglobulin G1- type. It blocks FGF ligand binding to the receptor, which causes the inhibition of downstream signaling pathways and promotes Antibody-dependent cell-mediated cytotoxicity (ADCC). Bemarituzumab induces receptor internalization and degradation.
FGFR2b is an isoform of fibroblast growth factor receptors. They are four signaling tyrosine kinase FGF receptors mediating interactions between cytosolic environment and mesenchyme. Activated FGFRs can phosphorylate tyrosine residues which are mediating specifically interaction with cytosolic adaptor proteins. FGFR2b receptor is overexpressed in 30% of HER2-negative Gastric and Gastroesophageal Cancers. Bemarituzumab is designed to target these specific cancer subtypes, which are using the FGF/FGFR pathway to promote transformation and proliferation of cells into tumors and to promote angiogenesis.
Bemarituzumab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.
ProteoGenix catalogue number PX-TA1492.
Target: Bemarituzumab Biosimilar – Anti-FGFR2 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Bemarituzumab Biosimilar – Anti-FGFR2 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
